Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25905782 | 0.86 | RXFP1 (0.45) | LIMK2HDAC4HTTGRM1MAPK14 | |
| SCHEMBL25041339 | 0.81 | LIMK2 (0.43) | LIMK2HDAC4HTTHPGD | |
| SCHEMBL25932371 | 0.77 | P4HTM (0.36) | HDAC4MAPTHPGDLMNA | |
| SCHEMBL22071184 | 0.77 | TP53 (0.48) | MAPTHPGDMEN1KMT2A | |
| SCHEMBL4503118 | 0.74 | CA1 (0.47) | LIMK2HDAC4HTTMAPTHPGD | |
| SCHEMBL12302001 | 0.74 | ALDH1A1 (0.48) | HDAC4HTTGRM1MAPTHPGD | |
| SCHEMBL13034674 | 0.73 | HDAC4 (0.49) | HDAC4GRM1HPGDKMT2A | |
| SCHEMBL25870881 | 0.73 | USP5 (0.50) | LIMK2HDAC4HTTMAPTHPGD | |
| SCHEMBL19538508 | 0.72 | MAPT (0.46) | MAPTHPGDMEN1LMNAKMT2A | |
| SCHEMBL394512 | 0.72 | HSD11B1 (0.53) | LIMK2HDAC4MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | LIMK2 1110/4885HDAC4 1116/4885HTT 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.